Premium
Secukinumab improves the signs and symptoms of moderate‐to‐severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double‐blind, placebo‐controlled, phase 2 dose‐ranging study
Author(s) -
Sigurgeirsson B.,
Kircik L.,
Nemoto O.,
Mikazans I.,
Haemmerle S.,
Thurston H.J.,
Papavassilis C.,
Richards H.B.
Publication year - 2014
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.12343
Subject(s) - medicine , secukinumab , dermatology , placebo , psoriasis , plaque psoriasis , randomized controlled trial , surgery , alternative medicine , pathology , psoriatic arthritis
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom